1.Chambers, C et al. (2014) Pertussis surveillance trends in British Columbia, Canada, over a 20-year Period: 1993–2013. Canada Communicable Disease Report 40, 31–41.
2Black, RE et al. (2010) Pertussis vaccines: WHO position paper. The Weekly Epidemiological Record 85, 385–400.
3.Paksu, MS et al. (2013) Fulminant pertussis in very young infants: two cases and review of the literature. The Turkish Journal of Pediatrics 55, 426–429.
4.Díez-Domingo, J et al. (2004) Incidence of pertussis in persons < or =15 years of age in Valencia, Spain: seroprevalence of antibodies to pertussis toxin (PT) in children, adolescents and adults. Journal of Infection 49, 242–247.
5.Gil, A et al. (2001) Hospital admissions for pertussis in Spain, 1995–1998. Vaccine 19, 4791–4794.
6.Comité asesor de vacunas de la Asociación Española de Pediatría (2006) Calendario de vacunación de la Asociación Española de Pediatría: recomendaciones 2006. Anales de Pediatría 64, 74–77.
9.Briss, PA et al. (2000) Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community Preventive Services. American Journal of Preventive Medicine 18, 97–140.
10.Szilagyi, PG et al. (2000) Effect of patient reminder/recall interventions on immunization rates: a review. Journal of the American Medical Association 284, 1820–1827.
11.Fiks, AG et al. (2013) Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics 131, 1114–1124.
14.Guiso, N et al. (2016) Surveillance of pertussis: methods and implementation. Expert Review of Anti-infective Therapy 14, 657–667.
15.Espy, MJ et al. (2006) Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clinical Microbiology Reviews 19, 165–256.
16.Guiso, N et al. (2011) What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. European Journal of Clinical Microbiology 30, 307–312.
18.Campins, M et al. (2013) Whooping cough in Spain. Current epidemiology, prevention and control strategies. Recommendations by the Pertussis Working Group. Enfermedades Infecciosas y Microbiología Clínica 31, 240–253.
19.Taranger, J et al. (1997) Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. The Pediatric Infectious Disease Journal 16, 180–184.
20.Simondon, F et al. (1997) A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15, 1606–1612.
21.Salmaso, S et al. (2001) Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 108, E81.
22.Guiso, N et al. (2017) Whooping cough surveillance in France in pediatric private practice in 2006–2015. Vaccine 35, 6083–6088.
23.Domenech de Cellès, M et al. (2018) The impact of past vaccination coverage and immunity on pertussis resurgence. Science Translational Medicine 10, 434.
24.Radke, S et al. (2017) Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand. Vaccine 35, 177–183.
25.Rigo-Medrano, MV et al. (2016) Acellular vaccines (DTPa/dTpa) against whooping cough, protection duration. Enfermedades Infecciosas y Microbiología Clínica 34, 23–28.
26.Robert, E et al. (2014) Vaccination coverage for infants: cross-sectional studies in two regions of Belgium. BioMed Research International 2014, 838907.
27.Barber, A et al. (2017) Coverage with tetanus, diphtheria, and acellular pertussis vaccine and influenza vaccine among pregnant women – Minnesota, March 2013-December 2014. Morbidity and Mortality Weekly Report 66, 56–59.
28.Hill, HA et al. (2016) Vaccination coverage among children aged 19–35 months – United States, 2015. Morbidity and Mortality Weekly Report 65, 1065–1071.
29.Winter, K et al. (2015) Risk factors associated with infant deaths from pertussis: a case-control study. Clinical Infectious Diseases 61, 1099–1106.
30.Warfel, JM et al. (2014) Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proceedings of the National Academy of Sciences of the USA 111, 787–792.
31.McNamara, LA et al. (2017) Reduced severity of pertussis in persons with age-appropriate pertussis vaccination-United States, 2010–2012. Clinical Infectious Diseases 65, 811–818.
32.Zycinska, K et al. (2017) Whooping cough in adults: a series of severe cases. Advances in Experimental Medicine and Biology 955, 47–50.
33.Moreno Samos, M et al. (2015) Incidence and severity of pertussis in infants with a respiratory syncytial virus infection. Enfermedades Infecciosas y Microbioliología Clínica 33, 476–479.
34.Reinton, N et al. (2013) Respiratory tract infections during the 2011 Mycoplasma pneumoniae epidemic. European Journal of Clinical Microbiology & Infectious Diseases 32, 835–840.
35.Koepke, R et al. (2014) Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. The Journal of Infectious Diseases 210, 942–953.
36.Klein, NP et al. (2017) Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine 35, 3395–3400.
37.Vermeulen, F et al. (2013) Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine 31, 1981–1986.
38.Edelman, KJ et al. (2004) Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clinical Infectious Diseases 39, 179–185.
39.Lu, PJ et al. (2017) Impact of provider recommendation on Tdap vaccination of adolescents aged 13–17 years. American Journal of Preventive Medicine 53, 373–384.